ENDOMETRIN (progesterone) by Ferring Pharmaceuticals. Approved for progesterone [epc]. First approved in 2007.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
ENDOMETRIN (progesterone) is a vaginal insert containing micronized progesterone, a naturally occurring hormone used to support the luteal phase in assisted reproductive technology (ART) cycles. It is indicated for progesterone supplementation in women undergoing fertility treatment. The drug works by providing exogenous progesterone to prepare and maintain the endometrium for embryo implantation.
Product approaching loss of exclusivity with minimal recent Medicare claims, suggesting a niche, declining market presence and likely reduced commercial team investment.
Progesterone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone
Cycle-to-cycle Variability of Progesterone in the Endometrium in Patients Undergoing an Euploid Blastocyst Transfer in a Hormone Replacement Therapy (HRT) Cycle (PROMICOFET)
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
Exogenous Progesterone as Ovulation Trigger
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
Worked on ENDOMETRIN at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moENDOMETRIN currently shows zero linked job opportunities, reflecting its mature, LOE-approaching market status and niche fertility indication. Roles on this product would be highly specialized, focused on defending market share in a competitive segment rather than growth initiatives.